Theriva Biologics (TOVX) has announced encouraging top-line results from its VIRAGE trial, sending its stock up over 40% to $1.92 in premarket trading Wednesday.
VIRAGE is a phase IIb trial testing the company's lead drug candidate, VCN-01, in combination with standard of care (SoC) chemotherapy (gemcitabine and nab-paclitaxel), as a first-line treatment for patients with metastatic pancreatic cancer - a group for whom this chemotherapy is the recommended first-line treatment option.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.